Date: 2018-05-02
Type of information: Collaboration agreement
Compound:
- antibodies against biological targets selected by aTen.
Company: Iontas (UK) aTen Therapeutics (UK)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details:
- • On May 2, 2018, Iontas, a leader in the discovery and optimisation of fully human antibodies, and aTen Therapeutics, a private biopharmaceutical company developing next-generation antibodies for the treatment of cancer, have entered into a strategic collaboration. Under the agreement Iontas will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen.
Financial terms:
Latest news:
Is general: Yes
